Achmea Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Achmea Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,036	Closed	-$653K	–	595
2019 Q4	$653K	Hold	6,036	–	–	0.03%	419
2019 Q3	$591K	Hold	6,036	–	–	0.02%	414
2019 Q2	$791K	Hold	6,036	–	–	0.03%	397
2019 Q1	$816K	Hold	6,036	–	–	0.03%	355
2018 Q4	$588K	Hold	6,036	–	–	0.03%	369
2018 Q3	$839K	Hold	6,036	–	–	0.03%	380
2018 Q2	$749K	Hold	6,036	–	–	0.03%	397
2018 Q1	$672K	Hold	6,036	–	–	0.02%	423
2017 Q4	$721K	Buy	6,036 +1,022	+20%	+$124K	0.02%	419
2017 Q3	$703K	Hold	5,014	–	–	0.04%	368
2017 Q2	$610K	Hold	5,014	–	–	0.04%	386
2017 Q1	$608K	Buy	+5,014	New	+$646K	0.03%	421

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Achmea Investment Management's ALXN Position: Q1 2020 in Review

Achmea Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 6,036 shares — an estimated $653K sold.

Achmea Investment Management first reported a position in ALXN in Q1 2017 and held it in 12 quarters. The position peaked at $839K in Q3 2018. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

Achmea Investment Management reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Achmea Investment Management sold 6,036 Alexion Pharmaceuticals shares in Q1 2020, an estimated $653K.
Achmea Investment Management first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 12 quarters.
Achmea Investment Management's Alexion Pharmaceuticals position peaked at $839K in Q3 2018.
654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Achmea Investment Management's 13F filing for Q1 2020, filed 13 May 2020.